GlaxoSmithKline (GSK) and iTeos Therapeutics have embarked on a Phase 3 clinical trial titled ‘GALAXIES Lung-301’ to assess the safety and efficacy of belrestotug combined with dostarlimab ...

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung ...

GSK, iTeos End Anti-TIGIT Drug Development In a separate press release, the company announced that it is ending the development of the anti-TIGIT antibody belrestotug, which was being developed in ...

GSK and iTeos plan to start combination studies of EOS-448 with dostarlimab in 2022. GSK’608 (anti-CD96 being developed in collaboration with 23andMe) is in phase I as monotherapy and in ...

GSK and iTeos plan to start combination studies of EOS-448 with dostarlimab in 2022. GSK'608-anti-CD96 being developed in collaboration with 23andMe- is in phase I as monotherapy and in ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK ...

Shares of iTeos Therapeutics jumped by more than 35% on the news that it has licensed its cancer antibody to pharmaceutical giant GlaxoSmithKline, which is paying $625 million up front for the drug.

News provided by iTeos Therapeutics Inc. Nov 10, 2022, 4:01 PM ET – Initiated a randomized Phase 2 trial evaluating anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and GSK’s anti-PD-1 ...

WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the ...

GSK, iTeos End Anti-TIGIT Drug Development In a separate press release, the company announced that it is ending the development of the anti-TIGIT antibody belrestotug, which was being developed in ...